双特异性抗体彻底改变了乳腺癌的治疗方法:一个全面的概述
Huan-Rong Lan1, Min Chen2, Shi-Ya Yao3
1Department of Surgical Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.
Frontiers in immunology
|December 19, 2023
概括
双特异性抗体 (BsAbs) 通过向多个抗原,为乳腺癌 (BCa) 治疗提供了一个有希望的新策略. 这些新型疗法增强了抗癌活性和免疫反应,在临床研究中显示出显著的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 乳腺癌 (BCa) 是一种普遍而复杂的疾病,需要创新的治疗策略.
- 双特异性抗体 (BsAbs) 正因其双重向能力而成为一个有前途的方法.
- BsAbs可以通过向瘤抗原,吸引免疫细胞或阻断信号通路来增强抗癌活性.
研究的目的:
- 审查关于在乳腺癌 (BCa) 治疗中使用双特异抗体 (BsAbs) 的最新证据.
- 总结与BCa疗法中的BsAbs相关的挑战和机会.
- 突出BsAbs在改善抗癌活性和免疫反应方面的潜力.
主要方法:
- 对BCa的BsAbs进行临床前和临床研究的审查.
- 针对人类表皮生长因子受体2 (HER2) 阳性BCa细胞的BsAbs的分析.
- 对针对PD-1/PD-L1通路的BsAbs进行评估,以克服免疫抑制.
- 评估涉及BsAbs与化疗,向疗法和免疫检查点抑制剂 (ICI) 的组合疗法.
主要成果:
- 向HER2的BsAbs可以有效地将免疫细胞重定向到HER2阳性BCa细胞,从而导致瘤细胞死亡.
- 针对PD-1/PD-L1通路的BsAbs显示出增强免疫媒介瘤清除和克服免疫抑制的潜力.
- 与BsAbs的组合疗法在临床前模型和早期临床试验中显示出协同效应,强调了它们的治疗效用.
结论:
- 双特异性抗体 (BsAbs) 代表了乳腺癌 (BCa) 治疗的重大进展.
- 对BSAbs挑战和机会的进一步研究将优化其临床应用.
- 对于改善乳腺癌患者的治疗结果,bsAbs具有相当大的前景.
更多相关视频
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.3K
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
9.0K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
